Kristina I Melkersson1. 1. Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. Kristina.Melkersson@ki.se
Abstract
OBJECTIVE: Treatment with the antipsychotic risperidone is frequently associated with hyperprolactinemia. The aim of this study was to evaluate the role of the main compound risperidone and its active 9-hydroxy metabolite on elevating prolactin levels. METHODS: Twenty patients with psychotic disorders, on therapy with risperidone, were studied. All patients had been receiving risperidone for at least 2.5 months, and the median daily dose of risperidone was 3 mg (range 1-10). Morning serum samples for prolactin were analyzed and investigated in relation to the serum concentrations of risperidone and 9-hydroxyrisperidone. RESULTS: Elevated prolactin levels were found in 17 (85%) of the patients. Levels of prolactin were positively correlated to the 9-hydroxyrisperidone serum concentration (r(s) = 0.48, p = 0.03) and to the daily dose of risperidone (r(s) = 0.51, p = 0.03), but did not correlate to the risperidone serum concentration. CONCLUSION: The present results suggest that 9-hydroxyrisperidone and not risperidone is the main contributor to the increased serum levels of prolactin observed in many risperidone-treated patients.
OBJECTIVE: Treatment with the antipsychotic risperidone is frequently associated with hyperprolactinemia. The aim of this study was to evaluate the role of the main compound risperidone and its active 9-hydroxy metabolite on elevating prolactin levels. METHODS: Twenty patients with psychotic disorders, on therapy with risperidone, were studied. All patients had been receiving risperidone for at least 2.5 months, and the median daily dose of risperidone was 3 mg (range 1-10). Morning serum samples for prolactin were analyzed and investigated in relation to the serum concentrations of risperidone and 9-hydroxyrisperidone. RESULTS: Elevated prolactin levels were found in 17 (85%) of the patients. Levels of prolactin were positively correlated to the 9-hydroxyrisperidone serum concentration (r(s) = 0.48, p = 0.03) and to the daily dose of risperidone (r(s) = 0.51, p = 0.03), but did not correlate to the risperidone serum concentration. CONCLUSION: The present results suggest that 9-hydroxyrisperidone and not risperidone is the main contributor to the increased serum levels of prolactin observed in many risperidone-treated patients.
Authors: C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel Journal: Schizophr Res Date: 2007-08-31 Impact factor: 4.939
Authors: Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost Journal: Clin Pharmacokinet Date: 2011-07 Impact factor: 6.447
Authors: Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap Journal: Clin Pharmacokinet Date: 2015-12 Impact factor: 6.447
Authors: Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen Journal: Eur J Clin Pharmacol Date: 2016-07-04 Impact factor: 2.953